Not checked for notices yet.

ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models

Teresa Lambe, Alexandra J. Spencer, Kelly M. Thomas and 41 more

Communications Biology · 2021

doi:10.1038/s42003-021-02443-0

References 36

1.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
2.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
3.
Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus · 2012
Corrected
4.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
5.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
6.
Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial · 2015
No notice
7.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
8.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
9.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
10.
Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults · 2018
Corrected
11.
Development of an inactivated vaccine candidate for SARS-CoV-2 · 2020
No notice
12.
SARS-CoV-2 infection protects against rechallenge in rhesus macaques · 2020
No notice
13.
DNA vaccine protection against SARS-CoV-2 in rhesus macaques · 2020
No notice
14.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
15.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
16.
Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques · 2020
No notice
17.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
18.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
19.
Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19 · 2020
No notice
20.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
21.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
22.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
23.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
24.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
25.
Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity · 2020
No notice
26.
Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19 · 2021
No notice
27.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
28.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
29.
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK · 2021
Corrected
30.
Dose-dependent response to infection with SARS-CoV-2 in the ferret model and evidence of protective immunity · 2021
No notice
31.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
32.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
33.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
34.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
35.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
36.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library

Cited by papers we hold 1

Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases · 2023
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.